Table 2.
Short-term efficacy of different induction therapy regimens.
| n (%) | G-CVP/CHOP (n=3) |
GB (n=27) |
G (n=6) |
G±chemo (n=36) |
R-CVP/CHOP (n=94) |
BR (n=13) |
R (n=4) |
R±chemo (n=111) |
|---|---|---|---|---|---|---|---|---|
| CR | 2 (66.7) | 18 (66.7) | 1 (16.7) | 21 (58.3) | 53 (56.4) | 8 (61.5) | 1 (25.0) | 62 (55.8) |
| PR | 1 (33.3) | 9 (33.3) | 5 (83.3) | 15 (41.7) | 31 (33.0) | 5 (38.5) | 2 (50.0) | 38 (34.2) |
| SD/PD | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 10 (10.6) | 0 (0) | 1 (25.0) | 11 (9.9) |
G, obinutuzumab; R, rituximab; CVP, cyclophosphamide, vincristine, prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; B, bendamustine; chemo, chemotherapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.